Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma

Akira Miyajima, Tomohiko Asano, Kaori Seta, Takako Asano, Narihiko Kakoi, Masamichi Hayakawa

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives. To determine the clinical implication of the loss of transforming growth factor-beta (TGF-β) receptor (TβR) expression for the pathologic features in renal cell carcinoma (RCC) and the prognosis of 62 patients (Stage I, 4; Stage II, 28; Stage III, 11; and Stage IV, 19) who underwent radical nephrectomy for RCC. Loss of expression in TβR could result in escape from the growth inhibitory effect of TGF-β in TGF-β-secreting cancer. Methods. TβR and apoptosis in the tumor were detected by immunohistochemistry using samples from 62 patients. We statistically investigated the relationship among the TβR expression pattern, pathologic features, and the prognosis of patients with RCC. Results. A loss of expression of TβR-I and TβR-II was identified in 29 patients (46.7%) and 31 patients (50.0%), respectively. Although the loss of TβR-I was not associated with clinical stage, the loss of TβR-II was associated with clinical stage (P <0.01). Univariate analysis of all patients demonstrated that Stage T3 or greater, clinical Stage III or greater, loss of TβR-II, and a tumor apoptotic index of less than 35 were associated with a significantly lower survival rate than their respective counterparts. Multivariate analysis showed that the only two significant prognostic factors were clinical stage and loss of TβR-II. In addition, TβR-negative RCC had significantly lower apoptosis than did TβR-positive RCC. Conclusions. These results suggest that a loss of TβR-II expression in the primary tumor is a significant prognostic factor in patients with RCC.

Original languageEnglish
Pages (from-to)1072-1077
Number of pages6
JournalUrology
Volume61
Issue number5
DOIs
Publication statusPublished - 2003 May 1
Externally publishedYes

Fingerprint

Transforming Growth Factor beta Receptors
Renal Cell Carcinoma
Transforming Growth Factor beta
Neoplasms
Apoptosis
Nephrectomy
Multivariate Analysis
Survival Rate
Immunohistochemistry
Growth

ASJC Scopus subject areas

  • Urology

Cite this

Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. / Miyajima, Akira; Asano, Tomohiko; Seta, Kaori; Asano, Takako; Kakoi, Narihiko; Hayakawa, Masamichi.

In: Urology, Vol. 61, No. 5, 01.05.2003, p. 1072-1077.

Research output: Contribution to journalArticle

Miyajima, Akira ; Asano, Tomohiko ; Seta, Kaori ; Asano, Takako ; Kakoi, Narihiko ; Hayakawa, Masamichi. / Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. In: Urology. 2003 ; Vol. 61, No. 5. pp. 1072-1077.
@article{ceab22679df44a8daae3a05d43befeba,
title = "Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma",
abstract = "Objectives. To determine the clinical implication of the loss of transforming growth factor-beta (TGF-β) receptor (TβR) expression for the pathologic features in renal cell carcinoma (RCC) and the prognosis of 62 patients (Stage I, 4; Stage II, 28; Stage III, 11; and Stage IV, 19) who underwent radical nephrectomy for RCC. Loss of expression in TβR could result in escape from the growth inhibitory effect of TGF-β in TGF-β-secreting cancer. Methods. TβR and apoptosis in the tumor were detected by immunohistochemistry using samples from 62 patients. We statistically investigated the relationship among the TβR expression pattern, pathologic features, and the prognosis of patients with RCC. Results. A loss of expression of TβR-I and TβR-II was identified in 29 patients (46.7{\%}) and 31 patients (50.0{\%}), respectively. Although the loss of TβR-I was not associated with clinical stage, the loss of TβR-II was associated with clinical stage (P <0.01). Univariate analysis of all patients demonstrated that Stage T3 or greater, clinical Stage III or greater, loss of TβR-II, and a tumor apoptotic index of less than 35 were associated with a significantly lower survival rate than their respective counterparts. Multivariate analysis showed that the only two significant prognostic factors were clinical stage and loss of TβR-II. In addition, TβR-negative RCC had significantly lower apoptosis than did TβR-positive RCC. Conclusions. These results suggest that a loss of TβR-II expression in the primary tumor is a significant prognostic factor in patients with RCC.",
author = "Akira Miyajima and Tomohiko Asano and Kaori Seta and Takako Asano and Narihiko Kakoi and Masamichi Hayakawa",
year = "2003",
month = "5",
day = "1",
doi = "10.1016/S0090-4295(02)02553-0",
language = "English",
volume = "61",
pages = "1072--1077",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma

AU - Miyajima, Akira

AU - Asano, Tomohiko

AU - Seta, Kaori

AU - Asano, Takako

AU - Kakoi, Narihiko

AU - Hayakawa, Masamichi

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Objectives. To determine the clinical implication of the loss of transforming growth factor-beta (TGF-β) receptor (TβR) expression for the pathologic features in renal cell carcinoma (RCC) and the prognosis of 62 patients (Stage I, 4; Stage II, 28; Stage III, 11; and Stage IV, 19) who underwent radical nephrectomy for RCC. Loss of expression in TβR could result in escape from the growth inhibitory effect of TGF-β in TGF-β-secreting cancer. Methods. TβR and apoptosis in the tumor were detected by immunohistochemistry using samples from 62 patients. We statistically investigated the relationship among the TβR expression pattern, pathologic features, and the prognosis of patients with RCC. Results. A loss of expression of TβR-I and TβR-II was identified in 29 patients (46.7%) and 31 patients (50.0%), respectively. Although the loss of TβR-I was not associated with clinical stage, the loss of TβR-II was associated with clinical stage (P <0.01). Univariate analysis of all patients demonstrated that Stage T3 or greater, clinical Stage III or greater, loss of TβR-II, and a tumor apoptotic index of less than 35 were associated with a significantly lower survival rate than their respective counterparts. Multivariate analysis showed that the only two significant prognostic factors were clinical stage and loss of TβR-II. In addition, TβR-negative RCC had significantly lower apoptosis than did TβR-positive RCC. Conclusions. These results suggest that a loss of TβR-II expression in the primary tumor is a significant prognostic factor in patients with RCC.

AB - Objectives. To determine the clinical implication of the loss of transforming growth factor-beta (TGF-β) receptor (TβR) expression for the pathologic features in renal cell carcinoma (RCC) and the prognosis of 62 patients (Stage I, 4; Stage II, 28; Stage III, 11; and Stage IV, 19) who underwent radical nephrectomy for RCC. Loss of expression in TβR could result in escape from the growth inhibitory effect of TGF-β in TGF-β-secreting cancer. Methods. TβR and apoptosis in the tumor were detected by immunohistochemistry using samples from 62 patients. We statistically investigated the relationship among the TβR expression pattern, pathologic features, and the prognosis of patients with RCC. Results. A loss of expression of TβR-I and TβR-II was identified in 29 patients (46.7%) and 31 patients (50.0%), respectively. Although the loss of TβR-I was not associated with clinical stage, the loss of TβR-II was associated with clinical stage (P <0.01). Univariate analysis of all patients demonstrated that Stage T3 or greater, clinical Stage III or greater, loss of TβR-II, and a tumor apoptotic index of less than 35 were associated with a significantly lower survival rate than their respective counterparts. Multivariate analysis showed that the only two significant prognostic factors were clinical stage and loss of TβR-II. In addition, TβR-negative RCC had significantly lower apoptosis than did TβR-positive RCC. Conclusions. These results suggest that a loss of TβR-II expression in the primary tumor is a significant prognostic factor in patients with RCC.

UR - http://www.scopus.com/inward/record.url?scp=0038639405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038639405&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(02)02553-0

DO - 10.1016/S0090-4295(02)02553-0

M3 - Article

C2 - 12736050

AN - SCOPUS:0038639405

VL - 61

SP - 1072

EP - 1077

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -